Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved ...

Since 2008, the FDA has approved 11 treatments for a rare genetic condition called hereditary angioedema (HAE), three of ...

The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' drug to prevent instances of severe ...

Ionis Pharmaceuticals won FDA approval for a drug that prevents painful swelling attacks triggered by a rare genetic ...

The FDA has granted approval for Ionis Pharmaceuticals’ Dawnzera (donidalorsen), for use in preventing hereditary angioedema ...

Dawnzera is the first and only RNA-targeted prophylactic therapy to be approved for hereditary angioedema in adults and ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $60.2, a high ...

Ionis Pharmaceuticals rose 2.38% after hours following a planned stock sale by its chief scientific officer under a Rule 10b5-1 plan.

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

H.C. Wainwright raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $70 from $65 and keeps a Buy rating on the shares following FDA ...

Barclays raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $58 from $57 and keeps an Overweight rating on the shares. The firm says Dawnzera was approved by the FDA on time with a ...

Ionis Pharmaceuticals (NASDAQ: IONS) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. In the table below, you'll find a summary of ...